TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17095943
Drug: Nutrient infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nutrient infusion in patients with feed intolerance
Study: 17095943
Drug: Nutrient infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nutrient infusion in patients with impaired renal function
Study: 9926181
Drug: i.v. ketoprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketoprofen (1 mg kg-1 followed by an infusion of 1 mg kg-1 over 2 h)
Study: 1693062
Drug: rG-CSF administered
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rG-CSF administered intravenously at a dose of 100 micrograms/m2
Study: 1693062
Drug: rG-CSF administered
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rG-CSF administered subcutaneously at a dose of 75 micrograms
Study: 1693062
Drug: rG-CSF administered
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rG-CSF administered subcutaneously at a dose of 100 micrograms/m2
Study: 1693062
Drug: rG-CSF administered
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rG-CSF administered subcutaneously at a dose of 125 micrograms
Study: 7387806
Drug: Incremental administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incremental administration of thiopentone (50‐mg increments every 15 s)
Study: 7387806
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of thiopentone (4‐mg kg‐1)
Study: 31875276
Drug: Subcutaneous pasireotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous pasireotide 600-μg twice daily
Study: 31875276
Drug: Subcutaneous pasireotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous pasireotide 900-μg twice daily
Study: 31125538
Drug: Anterior technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior technique with 2.7 mL of anesthetic
Study: 31125538
Drug: Anterior technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior technique with 1.8 mL of anesthetic
Study: 31125538
Drug: Conventional IANB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional IANB with 1.8 mL of anesthetic
Study: 31125538
Drug: Conventional IANB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional IANB with 2.7 mL of anesthetic
Study: 27173671
Drug: Front treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Front treatment (targeted product placed in the front)
Study: 27173671
Drug: Back treatment
Normalized name: Salicylic Acid 4.72 mL in 118 mL TOPICAL SPRAY [MARK. BACK UP PLAN ANTI-ACNE BACK TREATMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Back treatment (targeted product placed in the back)
Study: 27173671
Drug: Unboxed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unboxed treatment (targeted product presented unboxed)
Study: 23981052
Drug: Early follicular
Normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early follicular phase (low hormone levels)
Study: 23981052
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase (high hormone levels)
Study: 17901096
Drug: Daily clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily clinical assessment, prevalence surveys, randomized controlled trial settings
Study: 12447512
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg daily
Study: 10512345
Drug: Clotrimazole 1%
Normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 1% cream applied twice daily for 3 weeks
Study: 10512345
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg once weekly for 3 weeks
Study: 8835618
Drug: Chlorthalidone 23
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 23 mg
Study: 8835618
Drug: Chlorthalidone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (both doses)
Study: 6892984
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone)
Study: 23666915
Drug: Ipilimumab at
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab at 0.3 mg/kg
Study: 23666915
Drug: Ipilimumab at
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab at 3 mg/kg
Study: 23666915
Drug: Ipilimumab at
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab at 10 mg/kg
Study: 23666915
Drug: Ipilimumab at
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab at 10 mg/kg (treatment-naïve patients)
Study: 23666915
Drug: Ipilimumab at
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab at 10 mg/kg (retreatment upon disease progression)
Study: 17034372
Drug: Eflornithine cream
Normalized name: eflornithine Topical Cream
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eflornithine cream
Study: 17034372
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Eflornithine + laser)
Study: 9989685
Drug: Red yeast
Normalized name: red yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red yeast rice (2.4 g/d)
Study: 119975
Drug: Local nitrofurantoin
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local nitrofurantoin treatment
Study: 119975
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment of the vagina
Study: 25675664
Drug: Levobupivacaine infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine infiltration (5 ml, 50 mg/10 ml)
Study: 22436595
Drug: Psycho-educational and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-educational and cognitive behavioural stabilizing group treatment (experimental treatment; EXP) added to treatment as usual (TAU)
Study: 15866397
Drug: Ibuprofen 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 5% cream
Study: 11935040
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anti-CMV antibodies in IC
Study: 7872228
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g n-3 FAs/d for 6 weeks followed by 3 g/d for 12 weeks
Study: 29677641
Drug: UFT (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (oral tegafur-uracil) at 500-600 mg/day for 5 days followed by 2-day rest for 1 year
Study: 29677641
Drug: UFT (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (oral tegafur-uracil)
Study: 24002280
Drug: Micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powder (MNP) with iron (12.5 mg/d of iron)
Study: 19026262
Drug: Panic‐Focused Psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panic‐Focused Psychodynamic Therapy (PFPP)
Study: 19026262
Drug: Applied Relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied Relaxation Therapy (ART)
Study: 7955819
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion (0.0025 to 0.01 micrograms/kg/min) with ganglionic blockade (trimethaphan) in young subjects
Study: 7955819
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion (0.005 to 0.03 micrograms/kg/min) without ganglionic blockade
Study: 31764068
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo arm of VOICE trial
Study: 8237930
Drug: Ethanol injection
Normalized name: ethanol Injection
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol injection
Study: 24954607
Drug: Sodium tetradecyl
Normalized name: Sodium tetradecylsulfate
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium tetradecyl sulfate (STS) injection
Study: 22252206
Drug: Pentavalent human-bovine
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent human-bovine reassortant rotavirus vaccine (PRV)
Study: 18300064
Drug: Sequential presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential presentation of risks
Study: 15911729
Drug: Bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (400 mg once a day)
Study: 12896934
Drug: Active treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment: two injections of enzyme potentiated desensitisation, each comprising 200 Fishman units of beta glucuronidase, 50 pg 1,3‐cyclohexanediol, 50 ng protamine sulphate, and a mixed inhaled allergen extract in a total volume of 0.05 ml of buffered saline.
Study: 12896934
Drug: Placebo: two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: two injections of 0.05 ml buffered saline solution.
Study: 1832920
Drug: Mivacurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.15 mg kg-1
Study: 1832920
Drug: Mivacurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.2 mg kg-1
Study: 1832920
Drug: Mivacurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.2 mg kg-1 over 30 s
Study: 1832920
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion at 8-10 micrograms kg-1 min-1
Study: 1832920
Drug: Neostigmine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.04 mg kg-1
Study: 1832920
Drug: Edrophonium 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.75 mg kg-1
Study: 27864024
Drug: SQ HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ HDM SLIT tablet (10,000 JAU)
Study: 27864024
Drug: SQ HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ HDM SLIT tablet (20,000 JAU)
Study: 27864024
Drug: SQ HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ HDM SLIT tablet
Study: 26850270
Drug: Oral tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tenofovir (TFV)
Study: 26850270
Drug: Oral group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral group correlates
Study: 25148718
Drug: I-Gel™
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-Gel™
Study: 20647390
Drug: Oral lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lactoferrin (200 mg/day)
Study: 20647390
Drug: i.v. iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. iron (125 mg weekly)
Study: 17452390
Drug: Community pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacist intervention (two home visits within two to eight weeks of discharge, drug review, symptom self-management, and lifestyle advice)
Study: 15476202
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid supplementation during MTX therapy
Study: 15476202
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation during MTX therapy
Study: 9505927
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg twice daily (n = 19)
Study: 9505927
Drug: Celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 200 mg daily (n = 21)
Study: 7838448
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of sodium nitroprusside in experimental infarction
Study: 31820546
Drug: Standard heart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heart failure care (triple therapy)
Study: 26047615
Drug: Eurythmy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurythmy therapy A (EYT-A)
Study: 26047615
Drug: Eurythmy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurythmy therapy B (EYT-B)
Study: 21159892
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg/day
Study: 2653119
Drug: Cervical epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical epidural anesthesia (CEA) with 15 ml of 0.375% bupivacaine and 150 micrograms fentanyl.
Study: 2653119
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (GA) with 0.2 mg.kg‐1 flunitrazepam, 5 micrograms.kg‐1 fentanyl, intubation with 0.08 mg.kg‐1 vecuronium, and ventilation with nitrous oxide and oxygen (50% each). Further injections of 2 micrograms.kg‐1 fentanyl every 30 min.
Study: 29043911
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of alcohol
Study: 6362465
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of alcohol
Study: 31466942
Drug: Smartphone-enabled video-observed
Normalized name: Enablex
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Smartphone-enabled video-observed treatment
Study: 23934239
Drug: HCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG injection before IUI
Study: 23934239
Drug: HCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG injection after IUI
Study: 9730451
Drug: Intravesical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical mitomycin C (MMC) 30 mg, weekly for 4 weeks, then monthly for 5 months
Study: 9730451
Drug: Intravesical bacille
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical bacille Calmette‐Guérin (BCG), weekly for 6 weeks
Study: 8381
Drug: Three capsules
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three capsules containing 35 mg of ST-1435 (group A)
Study: 8381
Drug: Four capsules
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four capsules of ST-1435 (group B)
Study: 8381
Drug: Five capsules
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five capsules of ST-1435 (group C)
Study: 29310375
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of tetracycline ointment every 6 hours for 48 hours postoperatively
Study: 29310375
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no topical tetracycline)
Study: 25972817
Drug: Michael's game
Approvals — FDA: no, EMA: no, PMDA: no
Description: Michael's game (MG)
Study: 19404945
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methotrexate, sulfasalazine, and hydroxychloroquine with prednisolone
Study: 17380844
Drug: lercanidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: lercanidipine (10 mg/day)
Study: 17380844
Drug: hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide (25 mg/day)
Study: 13129444
Drug: Tomato lycopene
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato lycopene oleoresin (30 mg/d)
Study: 10323423
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (2 packages diluted in 2-3 L of water)
Study: 1902298
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with canned herring (lower dose of n-3 fatty acids)
Study: 6215008
Drug: Piperacillin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (150 mg/kg/day for urinary tract infections; 250 mg/kg/day for other infections)
Study: 6215008
Drug: Carbenicillin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenicillin (200 mg/kg/day for urinary tract infections; 450 mg/kg/day for other infections)
Study: 26018112
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (100 mg daily)
Study: 25740851
Drug: Matching yeast-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching yeast-based placebo tablets
Study: 23993469
Drug: Acarbose plus
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose plus metformin fixed-dose combination (FDC)
Study: 23993469
Drug: Acarbose monotherapy
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose monotherapy
Study: 20739581
Drug: Levothyroxine (LT4)
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT4) suppressive therapy
Study: 18437288
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of halphaCGRP (2 mug/min)
Study: 3888863
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg daily
Study: 10993487
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (200 mg daily)
Study: 10993487
Drug: d-alpha-tocopherol (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-alpha-tocopherol (700 mg daily)
Study: 1288514
Drug: Piroxicam +
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam + Ranitidine (300 mg nocte)
Study: 3885832
Drug: Metoprolol 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 15 mg intravenously followed by 200 mg daily orally
Study: 29090473
Drug: Quizartinib 40
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib 40 mg/d (DL1; n = 7)
Study: 29090473
Drug: Quizartinib 60
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib 60 mg/d (DL2; n = 6)
Study: 23083673
Drug: L paracasei
Approvals — FDA: no, EMA: no, PMDA: no
Description: L paracasei ST11 and B longum BL999 (ST11+BL999)
Study: 20029223
Drug: Fentanyl transdermal
Normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl transdermal patch (FP)
Study: 20029223
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anesthesia (IP)
Study: 15963867
Drug: Oral extended-release
Normalized name: Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral extended-release hydromorphone (HHER) administered q24h
Study: 15963867
Drug: Immediate-release hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release hydromorphone (HHIR) dosed four times daily
Study: 14673431
Drug: NSAIDs and
Normalized name: methenamine
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs and supplements
Study: 14673431
Drug: Chondroprotective supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroprotective supplements
Study: 10545428
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CE) 0.625 mg/d
Study: 10545428
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CE and Vitamin E
Study: 8739514
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist 300 micrograms
Study: 8739514
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist 600 micrograms
Study: 2009118
Drug: CPM 4-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPM 4-day group (6 h daily CPM for 4 days in hospital followed by intermittent passive motion at home)
Study: 2009118
Drug: CPM 14-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPM 14-day group (6 h daily CPM for 14 days)
Study: 30522739
Drug: Methylphenidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.3 to 0.4 mg/kg (n = 22)
Study: 26946057
Drug: Tandem high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem high dose chemotherapy with epirubicin, cyclophosphamide, and thiotepa
Study: 26946057
Drug: Induction with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction with 2× epirubicin-cyclophosphamide followed by tandem HD chemotherapy
Study: 26946057
Drug: Dose dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose dense chemotherapy (4× epirubicin-cyclophosphamide followed by 3× cyclophosphamide-methotrexate-5-fluorouracil)
Study: 20460174
Drug: Alternative complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative complex list based randomisation solutions
Study: 17506136
Drug: VelaSmooth system
Approvals — FDA: no, EMA: no, PMDA: no
Description: VelaSmooth system treatment on one thigh